

**Amendments to the Claims:**

The listing of claims will replace all previous versions, and listings of claims in the application:

**Listing of Claims:**

1 - 18. (canceled)

19. (currently amended) A method of producing a ~~GBV-B~~ derived virus comprising:  
introducing into a host cell a recombinant ~~GBV-B~~ or chimeric ~~GBV-B~~ viral genome  
comprising a 3' terminal sequence of GBV-B, wherein the 3' terminal sequence  
comprises 50 contiguous nucleotides from SEQ ID NO:1; and  
culturing said host cell under conditions permitting production of a virus from said  
genome.

20. (previously presented) The method of claim 19, wherein said 3' terminal sequence  
comprises 100 contiguous nucleotides from SEQ ID NO:1.

21. (previously presented) The method of claim 20, wherein said 3' terminal sequence  
comprises SEQ ID NO:1.

22 - 28. (canceled)

29. (original) The method of claim 28, wherein said host cell is in an animal.

30. (previously presented) The method of claim 19, wherein said genome comprises  
recombinant RNA.

31. (previously presented) The method of claim 19, wherein said genome is encoded by  
recombinant DNA.

32. (original) The method of claim 19, further comprising the step of isolating virus from  
said host cell.

33. (original) The method of claim 32, wherein said virus is purified to homogeneity.

- 34 - 50. (canceled)
51. (previously presented) The method of claim 31, wherein said genome comprises at least 250 contiguous nucleotides of SEQ ID NO:2.
52. (previously presented) The method of claim 31, wherein said genome comprises at least 500 contiguous nucleotides of SEQ ID NO:2.
53. (previously presented) The method of claim 31, wherein said genome comprises at least 1000 contiguous nucleotides of SEQ ID NO:2.
54. (previously presented) The method of claim 31, wherein said genome comprises at least 5000 contiguous nucleotides of SEQ ID NO:2.
55. (previously presented) The method of claim 31, wherein said genome comprises SEQ ID NO:2.
56. (previously presented) A method of producing a GBV-B or chimeric GBV-B virus comprising:  
obtaining a virus produced by the method of claim 19;  
introducing the virus into a second host cell; and  
culturing said host cell under conditions permitting production of virus.
57. (new) A method of producing a virus comprising:  
introducing into a host cell a recombinant GBV-B or chimeric GBV-B viral genome comprising a 3' terminal sequence of GBV-B, wherein the 3' terminal sequence is at least 70% identical to SEQ ID NO:1; and  
maintaining said host cell under conditions permitting production of a virus from said genome.
58. (new) The method of claim 57, wherein the host cell is a liver cell.

59. (new) The method of claim 58, wherein the liver cell is in an animal.
60. (new) The method of claim 59, wherein the animal is a primate.
61. (new) The method of claim 60, wherein the primate is a non-human primate.
62. (new) The method of claim 60, wherein the primate is a tamarin.
63. (new) The method of claim 58, wherein the 3' terminal sequence is at least 80% identical to SEQ ID NO:1.
64. (new) The method of claim 63, wherein the 3' terminal sequence is at least 90% identical to SEQ ID NO:1.
65. (new) The method of claim 64, wherein the 3' terminal sequence is at least 95% identical to SEQ ID NO:1.
66. (new) The method of claim 65, wherein the 3' terminal sequence is SEQ ID NO:1.
67. (new) A method of producing a virus comprising:  
introducing into a liver cell a recombinant GBV-B or chimeric GBV-B viral genome comprising a 3' terminal sequence of GBV-B, wherein the 3' terminal sequence is at least 70% identical to SEQ ID NO:1; and  
maintaining said liver cell under conditions permitting production of a virus from said genome.
68. (new) A method of replicating a virus comprising:  
introducing into a liver cell a recombinant GBV-B or chimeric GBV-B viral genome comprising a 3' terminal sequence of GBV-B, wherein the 3' terminal sequence is at least 70% identical to SEQ ID NO:1; and  
maintaining said liver cell under conditions permitting replication of the recombinant viral genome.

- 69. (new) The method of claim 68, wherein the 3' terminal sequence is at least 80% identical to SEQ ID NO:1.
- 70. (new) The method of claim 69, wherein the 3' terminal sequence is at least 90% identical to SEQ ID NO:1.
- 71. (new) The method of claim 70, wherein the 3' terminal sequence is at least 95% identical to SEQ ID NO:1.
- 72. (new) The method of claim 71, wherein the 3' terminal sequence is SEQ ID NO:1.